Sphene Capital lifts AlzChem price target to EUR 204.5, keeps buy rating

Reuters2026/07/31 06:05

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Sphene Capital reiterated Buy on AlzChem, raised 24-month target to EUR 204.5 from EUR 193.4.
H1 2026 revenue rose 5.7% to EUR 303.9 million; EBITDA increased 14.2% to EUR 64.5 million; margin improved to 21.2%.
Specialty Chemicals revenue grew 10.1% to EUR 214.3 million; segment EBITDA margin expanded to 29.9% from 27.7%.
Report cited stronger cash conversion, mix shift toward higher-margin specialty products, capacity expansions on schedule.
Guidance for 2026 seen as achievable, with a buffer implied in the firm’s forecasts.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AlzChem Group AG published the original content used to generate this news brief via EQS News (Ref. ID: rc_26344) on July 31, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Sphene Capital lifts AlzChem price target to EUR 204.5, keeps buy rating

You may also like

Crypto prices